
Michelle M Mello

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8558864/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Do you mind if I record?: Perceptions and practice regarding patient requests to record clinic visits in oncology. Cancer, 2022, 128, 275-283.	2.0	5
2	U.S. Public Health Law — Foundations and Emerging Shifts. New England Journal of Medicine, 2022, 386, 805-808.	13.9	6
3	Vaccine Misinformation and the First Amendment—The Price of Free Speech. JAMA Health Forum, 2022, 3, e220732.	1.0	5
4	Incentives for COVID-19 vaccination. The Lancet Regional Health Americas, 2022, 8, 100205.	1.5	17
5	Population health science as a unifying foundation for translational clinical and public health research. SSM - Population Health, 2022, 18, 101047.	1.3	3
6	Assessment of Perioperative Outcomes Among Surgeons Who Operated the Night Before. JAMA Internal Medicine, 2022, 182, 720.	2.6	10
7	Protecting the Privacy of Reproductive Health Information After the Fall of <i>Roe v Wade</i> . JAMA Health Forum, 2022, 3, e222656.	1.0	18
8	Apology laws and malpractice liability: what have we learned?. BMJ Quality and Safety, 2021, 30, 64-67.	1.8	5
9	When Physicians Engage in Practices That Threaten the Nation's Health. JAMA - Journal of the American Medical Association, 2021, 325, 723.	3.8	7
10	Prospects for Enforcing Prohibitions on Off-Label Drug Promotion after United States v. Caronia: An Analysis of Litigated Cases. Journal of Health Politics, Policy and Law, 2021, 46, 487-504.	0.9	3
11	To Address Drug Affordability, Grab the Low-Hanging Fruit. JAMA Health Forum, 2021, 2, e210260.	1.0	0
12	How US law will evaluate artificial intelligence for covid-19. BMJ, The, 2021, 372, n234.	3.0	8
13	Announcing the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA. Lancet, The, 2021, 397, 1165-1167.	6.3	25
14	Choices in a Crisis — Individual Preferences among SARS-CoV-2 Vaccines. New England Journal of Medicine, 2021, 384, e62.	13.9	14
15	To Address Drug Affordability, Grab the Low-hanging Fruit. JAMA - Journal of the American Medical Association, 2021, 325, 1599.	3.8	2
16	Supporting Hospitals During a New Wave of COVID-19. Journal of Hospital Medicine, 2021, 16, 311-312.	0.7	0
17	Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs. JAMA Network Open, 2021, 4, e217075.	2.8	24
18	The Medical Liability Environment: Is It Really Any Worse for Hospitalists?. Journal of Hospital Medicine, 2021, 16, 446.	0.7	0

#	Article	IF	CITATIONS
19	Drug Pricing Reform in 2021—Going Big or Going Bipartisan?. JAMA Health Forum, 2021, 2, e212372.	1.0	2
20	Clinical trial transparency and data sharing among biopharmaceutical companies and the role of company size, location and product type: a cross-sectional descriptive analysis. BMJ Open, 2021, 11, e053248.	0.8	8
21	Incorporating Health Equity Into COVID-19 Reopening Plans: Policy Experimentation in California. American Journal of Public Health, 2021, 111, 1481-1488.	1.5	12
22	Public Health Law after Covid-19. New England Journal of Medicine, 2021, 385, 1153-1155.	13.9	13
23	The Political and Judicial Battles Over Mask Mandates for Schools. JAMA Health Forum, 2021, 2, e214192.	1.0	1
24	Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA. Lancet, The, 2021, 398, 2186-2192.	6.3	106
25	Barriers to Ensuring Access to Affordable Prescription Drugs. Annual Review of Pharmacology and Toxicology, 2020, 60, 275-289.	4.2	5
26	The Missing Piece — SARS-CoV-2 Testing and School Reopening. New England Journal of Medicine, 2020, 383, e126.	13.9	24
27	Narrowing Vaccination Exemption Laws: Lessons From California and Beyond. Annals of Internal Medicine, 2020, 172, 358.	2.0	3
28	Partitioning the Curve — Interstate Travel Restrictions During the Covid-19 Pandemic. New England Journal of Medicine, 2020, 383, e83.	13.9	22
29	Attacks on Public Health Officials During COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 741.	3.8	58
30	Ensuring successful implementation of communication-and-resolution programmes. BMJ Quality and Safety, 2020, 29, 895-904.	1.8	11
31	Respecting Disability Rights — Toward Improved Crisis Standards of Care. New England Journal of Medicine, 2020, 383, e26.	13.9	44
32	Ethics and governance for digital disease surveillance. Science, 2020, 368, 951-954.	6.0	87
33	The Legal Authority for States' Stay-at-Home Orders. New England Journal of Medicine, 2020, 383, e29.	13.9	10
34	Diagnostic Testing for the Novel Coronavirus. JAMA - Journal of the American Medical Association, 2020, 323, 1437.	3.8	209
35	Standing Up against Gender Bias and Harassment — A Matter of Professional Ethics. New England Journal of Medicine, 2020, 382, 1385-1387.	13.9	28
36	Ensuring Uptake of Vaccines against SARS-CoV-2. New England Journal of Medicine, 2020, 383, 1296-1299.	13.9	77

#	Article	IF	CITATIONS
37	Waiting for data: Barriers to executing data use agreements. Science, 2020, 367, 150-152.	6.0	15
38	Malpractice Liability and Health Care Quality. JAMA - Journal of the American Medical Association, 2020, 323, 352.	3.8	44
39	Thinking Globally, Acting Locally — The U.S. Response to Covid-19. New England Journal of Medicine, 2020, 382, e75.	13.9	222
40	School Reopenings and the Community During the COVID-19 Pandemic. JAMA Health Forum, 2020, 1, e201294.	1.0	11
41	Oncologist experiences regarding patient-recorded clinical encounters: Implications for the patient-doctor relationship Journal of Clinical Oncology, 2020, 38, 290-290.	0.8	0
42	Big Data, Big Tech, and Protecting Patient Privacy. JAMA - Journal of the American Medical Association, 2019, 322, 1141.	3.8	85
43	Assessment of Out-of-Network Billing for Privately Insured Patients Receiving Care in In-Network Hospitals. JAMA Internal Medicine, 2019, 179, 1543.	2.6	50
44	The Role of Transparency in Patient Safety Improvement. , 2019, , 244-259.		0
45	Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices. BMJ: British Medical Journal, 2019, 366, l4217.	2.4	40
46	Multilevel legal approaches to obesity prevention: A conceptual and methodological toolkit. PLoS ONE, 2019, 14, e0220971.	1.1	6
47	â€~Poking the skunk': Ethical and medicoâ€legal concerns in research about patients' experiences of medical injury. Bioethics, 2019, 33, 948-957.	0.7	3
48	US Nationwide Disclosure of Industry Payments and Public Trust in Physicians. JAMA Network Open, 2019, 2, e191947.	2.8	40
49	Effect of the public disclosure of industry payments information on patients: results from a population-based natural experiment. BMJ Open, 2019, 9, e024020.	0.8	31
50	Changes in Practice among Physicians with Malpractice Claims. New England Journal of Medicine, 2019, 380, 1247-1255.	13.9	20
51	Association of Overlapping Surgery With Perioperative Outcomes. JAMA - Journal of the American Medical Association, 2019, 321, 762.	3.8	62
52	Association of Federal Mental Health Parity Legislation With Health Care Use and Spending Among High Utilizers of Services. Medical Care, 2019, 57, 245-255.	1.1	2
53	Legal Barriers to the Growth of Health Information Exchange—Boulders or Pebbles?. Milbank Quarterly, 2018, 96, 110-143.	2.1	63
54	Commentary: How Should Hospitals Respond to Surgeons' Requests to Schedule Overlapping Surgeries?. Neurosurgery, 2018, 82, E91-E98.	0.6	3

#	Article	IF	CITATIONS
55	Vaccination without Litigation — Addressing Religious Objections to Hospital Influenza-Vaccination Mandates. New England Journal of Medicine, 2018, 378, 785-788.	13.9	12
56	Disclosing Prescription-Drug Prices in Advertisements — Legal and Public Health Issues. New England Journal of Medicine, 2018, 379, 2290-2293.	13.9	5
57	Can Communication-And-Resolution Programs Achieve Their Potential? Five Key Questions. Health Affairs, 2018, 37, 1845-1852.	2.5	22
58	Effects Of A Communication-And-Resolution Program On Hospitals' Malpractice Claims And Costs. Health Affairs, 2018, 37, 1836-1844.	2.5	32
59	Beyond financial conflicts of interest: Institutional oversight of faculty consulting agreements at schools of medicine and public health. PLoS ONE, 2018, 13, e0203179.	1.1	5
60	Ethics of randomized trials in a public health emergency. PLoS Neglected Tropical Diseases, 2018, 12, e0006313.	1.3	12
61	HIPAA and Protecting Health Information in the 21st Century. JAMA - Journal of the American Medical Association, 2018, 320, 231.	3.8	118
62	Behind Schedule — Reconciling Federal and State Marijuana Policy. New England Journal of Medicine, 2018, 379, 501-504.	13.9	20
63	What Patients Expect and Deserve—Reply. JAMA Internal Medicine, 2018, 178, 578.	2.6	0
64	Clinical Trial Participants' Views of the Risks and Benefits of Data Sharing. New England Journal of Medicine, 2018, 378, 2202-2211.	13.9	162
65	Association of Unsolicited Patient Observations With the Quality of a Surgeon's Care. JAMA Surgery, 2017, 152, 530.	2.2	0
66	Public Awareness of and Contact With Physicians Who Receive Industry Payments: A National Survey. Journal of General Internal Medicine, 2017, 32, 767-774.	1.3	62
67	Medical Liability — Prospects for Federal Reform. New England Journal of Medicine, 2017, 376, 1806-1808.	13.9	12
68	Improving reconciliation following medical injury: a qualitative study of responses to patient safety incidents in New Zealand. BMJ Quality and Safety, 2017, 26, 788-798.	1.8	34
69	Outcomes In Two Massachusetts Hospital Systems Give Reason For Optimism About Communication-And-Resolution Programs. Health Affairs, 2017, 36, 1795-1803.	2.5	25
70	In search of global governance for research in epidemics. Lancet, The, 2017, 390, 1632-1633.	6.3	6
71	Patients' Experiences With Communication-and-Resolution Programs After Medical Injury. JAMA Internal Medicine, 2017, 177, 1595.	2.6	50
72	Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies. BMJ Open, 2017, 7, e017917.	0.8	46

#	Article	IF	CITATIONS
73	Length of Stay After Overlapping Surgery—Reply. JAMA - Journal of the American Medical Association, 2017, 318, 2140.	3.8	Ο
74	Drug Companies' Liability for the Opioid Epidemic. New England Journal of Medicine, 2017, 377, 2301-2305.	13.9	54
75	The Evolving Story of Overlapping Surgery. JAMA - Journal of the American Medical Association, 2017, 318, 233.	3.8	31
76	When are primary care physicians untruthful with patients? A qualitative study. AJOB Empirical Bioethics, 2017, 8, 32-39.	0.8	3
77	Testing the Immunity of the Firearm Industry to Tort Litigation. JAMA Internal Medicine, 2017, 177, 102.	2.6	4
78	Association Between State Medical Malpractice Environment and Surgical Quality and Cost in the United States. Annals of Surgery, 2016, 263, 1126-1132.	2.1	16
79	Sociodemographic Predictors of Vaccination Exemptions on the Basis of Personal Belief in California. American Journal of Public Health, 2016, 106, 172-177.	1.5	62
80	Case Outcomes in a Communication-and-Resolution Program in New York Hospitals. Health Services Research, 2016, 51, 2583-2599.	1.0	15
81	Challenges of Implementing a Communicationâ€andâ€Resolution Program Where Multiple Organizations Must Cooperate. Health Services Research, 2016, 51, 2550-2568.	1.0	20
82	Building a National Surveillance System for Malpractice Claims. Health Services Research, 2016, 51, 2642-2648.	1.0	8
83	Collaboration with Regulators to Support Quality and Accountability Following Medical Errors: The Communication and Resolution Program Certification Pilot. Health Services Research, 2016, 51, 2569-2582.	1.0	11
84	Prevalence and Characteristics of Physicians Prone to Malpractice Claims. New England Journal of Medicine, 2016, 374, 354-362.	13.9	114
85	Managing the Risks of Concurrent Surgeries. JAMA - Journal of the American Medical Association, 2016, 315, 1563.	3.8	52
86	Have Tobacco 21 Laws Come of Age?. New England Journal of Medicine, 2016, 374, 1601-1604.	13.9	40
87	Legal and Policy Interventions to Improve Patient Safety. Circulation, 2016, 133, 661-671.	1.6	18
88	Should Malpractice Settlements Be Secret?. JAMA Internal Medicine, 2015, 175, 1135.	2.6	5
89	Searching for Public Health Law's Sweet Spot: The Regulation of Sugar-Sweetened Beverages. PLoS Medicine, 2015, 12, e1001848.	3.9	26
90	Medical Liability and Reporting Malpractice Payments—Reply. JAMA - Journal of the American Medical Association, 2015, 313, 1058.	3.8	2

#	Article	IF	CITATIONS
91	Half-Baked — The Retail Promotion of Marijuana Edibles. New England Journal of Medicine, 2015, 372, 989-991.	13.9	88
92	Shifting Vaccination Politics — The End of Personal-Belief Exemptions in California. New England Journal of Medicine, 2015, 373, 785-787.	13.9	68
93	Supporting Those Who Go to Fight Ebola. PLoS Medicine, 2015, 12, e1001781.	3.9	7
94	Institutional Oversight of Faculty-Industry Consulting Relationships in U.S. Medical Schools: A Delphi Study. Journal of Law, Medicine and Ethics, 2015, 43, 383-96.	0.4	5
95	How Policy Makers Can Smooth The Way For Communication-And- Resolution Programs. Health Affairs, 2014, 33, 11-19.	2.5	36
96	Tobacco 21 — An Idea Whose Time Has Come. New England Journal of Medicine, 2014, 370, 295-297.	13.9	39
97	What Is a Public Health "Emergency�. New England Journal of Medicine, 2014, 371, 986-988.	13.9	36
98	Making the Case for Health-Enhancing Laws after Bloomberg. Hastings Center Report, 2014, 44, 8-8.	0.7	3
99	Communication-And-Resolution Programs: The Challenges And Lessons Learned From Six Early Adopters. Health Affairs, 2014, 33, 20-29.	2.5	78
100	Implementing Hospital-Based Communication-And-Resolution Programs: Lessons Learned In New York City. Health Affairs, 2014, 33, 30-38.	2.5	25
101	Clinical Trials and the Right to Remain Silent. JAMA Internal Medicine, 2014, 174, 1505.	2.6	1
102	The Medical Liability Climate and Prospects for Reform. JAMA - Journal of the American Medical Association, 2014, 312, 2146.	3.8	75
103	A New Era in Noninvasive Prenatal Testing. New England Journal of Medicine, 2013, 369, 499-501.	13.9	93
104	Gene Patenting — The Supreme Court Finally Speaks. New England Journal of Medicine, 2013, 369, 869-875.	13.9	58
105	Breast Cancer Screening. JAMA - Journal of the American Medical Association, 2013, 309, 2555.	3.8	16
106	A New Era in Noninvasive Prenatal Testing. New England Journal of Medicine, 2013, 369, 2164-2165.	13.9	18
107	Preparing for Responsible Sharing of Clinical Trial Data. New England Journal of Medicine, 2013, 369, 1651-1658.	13.9	155
108	Sunlight as Disinfectant — New Rules on Disclosure of Industry Payments to Physicians. New England Journal of Medicine, 2013, 368, 2052-2054.	13.9	63

#	Article	IF	CITATIONS
109	Talking with Patients about Other Clinicians' Errors. New England Journal of Medicine, 2013, 369, 1752-1757.	13.9	67
110	Defensive Medicine—Legally Necessary but Ethically Wrong?. JAMA Internal Medicine, 2013, 173, 1056.	2.6	21
111	Editors' Introduction. Journal of Health Politics, Policy and Law, 2013, 38, 629-643.	0.9	Ο
112	FDA Regulation of Off-label Drug Promotion Under Attack. JAMA - Journal of the American Medical Association, 2013, 309, 445.	3.8	11
113	The Politics of HPV Vaccination Policy Formation in the United States. Journal of Health Politics, Policy and Law, 2013, 38, 645-681.	0.9	37
114	Critical Opportunities for Public Health Law: A Call for Action. American Journal of Public Health, 2013, 103, 1979-1988.	1.5	25
115	The Taxing Power and the Public's Health. New England Journal of Medicine, 2012, 367, 1777-1779.	13.9	2
116	Ethical Considerations in Studying Drug Safety — The Institute of Medicine Report. New England Journal of Medicine, 2012, 367, 959-964.	13.9	21
117	Ejecting trans fat from New York City restaurants. Nature Reviews Endocrinology, 2012, 8, 633-635.	4.3	1
118	Disclosure-And-Resolution Programs That Include Generous Compensation Offers May Prompt A Complex Patient Response. Health Affairs, 2012, 31, 2681-2689.	2.5	27
119	Pharmaceutical Companies' Role in State Vaccination Policymaking: The Case of Human Papillomavirus Vaccination. American Journal of Public Health, 2012, 102, 893-898.	1.5	37
120	Legal and policy approaches to the obesity epidemic. Surgery for Obesity and Related Diseases, 2012, 8, 507-513.	1.0	5
121	Disclosure, Apology, and Offer Programs: Stakeholders' Views of Barriers to and Strategies for Broad Implementation. Milbank Quarterly, 2012, 90, 682-705.	2.1	46
122	New horizons in pharmaceutical regulation. Nature Reviews Drug Discovery, 2012, 11, 501-502.	21.5	8
123	Does Tort Law Improve the Health of Newborns, or Miscarry? A Longitudinal Analysis of the Effect of Liability Pressure on Birth Outcomes. Journal of Empirical Legal Studies, 2012, 9, 217-245.	0.5	23
124	New Directions in Medical Liability Reform. New England Journal of Medicine, 2011, 364, 1564-1572.	13.9	97
125	Medical Malpractice in the Military. New England Journal of Medicine, 2011, 365, 664-670.	13.9	3
126	Medical Malpractice Liability in the Age of Electronic Health Records. Survey of Anesthesiology, 2011, 55, 317-319.	0.1	3

#	Article	IF	CITATIONS
127	"Pay for Delay―Settlements of Disputes over Pharmaceutical Patents. New England Journal of Medicine, 2011, 365, 1439-1445.	13.9	23
128	Relationship between Quality of Care and Negligence Litigation in Nursing Homes. New England Journal of Medicine, 2011, 364, 1243-1250.	13.9	34
129	Restrictions on the Use of Prescribing Data for Drug Promotion. New England Journal of Medicine, 2011, 365, 1248-1254.	13.9	19
130	Strategies and Practices in Off-Label Marketing of Pharmaceuticals: A Retrospective Analysis of Whistleblower Complaints. PLoS Medicine, 2011, 8, e1000431.	3.9	88
131	Administrative compensation for medical injuries: lessons from three foreign systems. Issue Brief (Commonwealth Fund), 2011, 14, 1-18.	0.9	12
132	Malpractice Reform—Opportunities for Leadership by Health Care Institutions and Liability Insurers. Obstetrics and Gynecology, 2010, 116, 1254-1256.	1.2	0
133	Defensive Medicine and Tort Reform: A Wide View. Journal of General Internal Medicine, 2010, 25, 380-381.	1.3	30
134	Making the Case for Laws That Improve Health: A Framework for Public Health Law Research. Milbank Quarterly, 2010, 88, 169-210.	2.1	156
135	National Costs Of The Medical Liability System. Health Affairs, 2010, 29, 1569-1577.	2.5	409
136	Federal Trade Commission Regulation of Food Advertising to Children: Possibilities for a Reinvigorated Role. Journal of Health Politics, Policy and Law, 2010, 35, 227-276.	0.9	24
137	The Flaws In State â€~Apology' And â€~Disclosure' Laws Dilute Their Intended Impact On Malpractice Suit Health Affairs, 2010, 29, 1611-1619.	^{S.} 2.5	69
138	The Havasupai Indian Tribe Case — Lessons for Research Involving Stored Biologic Samples. New England Journal of Medicine, 2010, 363, 204-207.	13.9	320
139	Regulation of Smoking in Public Housing. New England Journal of Medicine, 2010, 362, 2319-2325.	13.9	73
140	Whistle-Blowers' Experiences in Fraud Litigation against Pharmaceutical Companies. New England Journal of Medicine, 2010, 362, 1832-1839.	13.9	46
141	HPV Vaccination Mandates — Lawmaking amid Political and Scientific Controversy. New England Journal of Medicine, 2010, 363, 785-791.	13.9	90
142	Medical Malpractice Liability in the Age of Electronic Health Records. New England Journal of Medicine, 2010, 363, 2060-2067.	13.9	89
143	Gene Patenting — Is the Pendulum Swinging Back?. New England Journal of Medicine, 2010, 362, 1855-1858.	13.9	21
144	Malpractice Reform — Opportunities for Leadership by Health Care Institutions and Liability Insurers. New England Journal of Medicine, 2010, 362, 1353-1356.	13.9	43

#	Article	IF	CITATIONS
145	New York City's War on Fat. New England Journal of Medicine, 2009, 360, 2015-2020.	13.9	38
146	Disclosing Harmful Medical Errors to Patients. Chest, 2009, 136, 897-903.	0.4	35
147	Shifting Terrain in the Regulation of Off-Label Promotion of Pharmaceuticals. New England Journal of Medicine, 2009, 360, 1557-1566.	13.9	51
148	The Role of Medical Liability Reform in Federal Health Care Reform. New England Journal of Medicine, 2009, 361, 1-3.	13.9	185
149	Incremental Health Care Reform. JAMA - Journal of the American Medical Association, 2009, 301, 1814.	3.8	3
150	Commentary: A Legal Perspective on Diabetes Surveillance—Privacy and the Police Power. Milbank Quarterly, 2009, 87, 575-580.	2.1	1
151	Relationship Between Malpractice Litigation Pressure and Rates of Cesarean Section and Vaginal Birth After Cesarean Section. Medical Care, 2009, 47, 234-242.	1.1	175
152	RATIONALIZING VACCINE INJURY COMPENSATION. Bioethics, 2008, 22, 32-42.	0.7	24
153	A Longitudinal Analysis of the Impact of Liability Pressure on the Supply of Obstetrician-Gynecologists. Journal of Empirical Legal Studies, 2008, 5, 21-53.	0.5	26
154	Administrative Compensation of Medical Injuries: A Hardy Perennial Blooms Again. Journal of Health Politics, Policy and Law, 2008, 33, 725-760.	0.9	17
155	Obesity—personal choice or public health issue?. Nature Clinical Practice Endocrinology and Metabolism, 2008, 4, 2-3.	2.9	9
156	Wellness Programs and Lifestyle Discrimination — The Legal Limits. New England Journal of Medicine, 2008, 359, 192-199.	13.9	66
157	The Interplay of Public Health Law and Industry Self-Regulation: The Case of Sugar-Sweetened Beverage Sales in Schools. American Journal of Public Health, 2008, 98, 595-604.	1.5	74
158	Adjudicating Severe Birth Injury Claims in Florida and Virginia: The Experience of a Landmark Experiment in Personal Injury Compensation. American Journal of Law and Medicine, 2008, 34, 493-537.	0.5	16
159	Compact versus Contract — Industry Sponsors' Obligations to Their Research Subjects. New England Journal of Medicine, 2007, 356, 2737-2743.	13.9	14
160	Regulatory and Judicial Oversight of Nonprofit Hospitals. New England Journal of Medicine, 2007, 356, 625-631.	13.9	7
161	Sunshine Laws and the Pharmaceutical Industry. JAMA - Journal of the American Medical Association, 2007, 297, 1255.	3.8	17
162	Disclosure Of Medical Injury To Patients: An Improbable Risk Management Strategy. Health Affairs, 2007, 26, 215-226.	2.5	108

#	Article	IF	CITATIONS
163	Changes In Physician Supply And Scope Of Practice During A Malpractice Crisis: Evidence From Pennsylvania. Health Affairs, 2007, 26, w425-w435.	2.5	24
164	Geographic Variation in Informed Consent Law: Two Standards for Disclosure of Treatment Risks. Journal of Empirical Legal Studies, 2007, 4, 103-124.	0.5	29
165	Who Pays for Medical Errors? An Analysis of Adverse Event Costs, the Medical Liability System, and Incentives for Patient Safety Improvement. Journal of Empirical Legal Studies, 2007, 4, 835-860.	0.5	38
166	Claims, Errors, and Compensation Payments in Medical Malpractice Litigation. New England Journal of Medicine, 2006, 354, 2024-2033.	13.9	722
167	Liability, Patient Safety, and Defensive Medicine: What Does the Future Hold?. , 2006, , 93-114.		3
168	"Health Courts" and Accountability for Patient Safety. Milbank Quarterly, 2006, 84, 459-492.	2.1	58
169	Obesity — The New Frontier of Public Health Law. New England Journal of Medicine, 2006, 354, 2601-2610.	13.9	181
170	Medical-Process Patents — Monopolizing the Delivery of Health Care. New England Journal of Medicine, 2006, 355, 2036-2041.	13.9	16
171	THE ROLE OF CLINICAL GUIDELINES IN MEDICAL NEGLIGENCE LITIGATION: A SHIFT FROM THE BOLAM STANDARD?. Medical Law Review, 2006, 14, 321-366.	0.2	69
172	Effects of a Malpractice Crisis on Specialist Supply and Patient Access to Care. Annals of Surgery, 2005, 242, 621-628.	2.1	69
173	Managing Malpractice Crises. Journal of Law, Medicine and Ethics, 2005, 33, 414-415.	0.4	1
174	The Future of Surgery: Today's Residents Speak. Journal of Surgical Education, 2005, 62, 543-546.	0.7	16
175	Fostering Rational Regulation of Patient Safety. Journal of Health Politics, Policy and Law, 2005, 30, 375-426.	0.9	30
176	Defensive Medicine Among High-Risk Specialist Physicians in a Volatile Malpractice Environment. JAMA - Journal of the American Medical Association, 2005, 293, 2609.	3.8	957
177	Academic Medical Centers' Standards for Clinical-Trial Agreements with Industry. New England Journal of Medicine, 2005, 352, 2202-2210.	13.9	121
178	Researchers' Views of the Acceptability of Restrictive Provisions in Clinical Trial Agreements with Industry Sponsors. Accountability in Research, 2005, 12, 163-191.	1.6	12
179	Legal Concerns and the Influenza Vaccine Shortage. JAMA - Journal of the American Medical Association, 2005, 294, 1817.	3.8	15
180	Effects of a Professional Liability Crisis on Residents' Practice Decisions. Obstetrics and Gynecology, 2005, 105, 1287-1295.	1.2	37

#	Article	IF	CITATIONS
181	The Pharmaceutical Industry versus Medicaid — Limits on State Initiatives to Control Prescription-Drug Costs. New England Journal of Medicine, 2004, 350, 608-613.	13.9	17
182	Financial Conflicts of Interest in Physicians' Relationships with the Pharmaceutical Industry — Self-Regulation in the Shadow of Federal Prosecution. New England Journal of Medicine, 2004, 351, 1891-1900.	13.9	198
183	Caring For Patients In A Malpractice Crisis: Physician Satisfaction And Quality Of Care. Health Affairs, 2004, 23, 42-53.	2.5	87
184	Medical malpractice as an epidemiological problem. Social Science and Medicine, 2004, 59, 39-46.	1.8	24
185	Decision making and satisfaction with care in the pediatric intensive care unit: Findings from a controlled clinical trial. Pediatric Critical Care Medicine, 2004, 5, 40-47.	0.2	20
186	The experience of a community representative on an ethics consult team. Journal of Clinical Ethics, 2004, 15, 296-301.	0.1	1
187	Conflict in the care of patients with prolonged stay in the ICU: types, sources, and predictors. Intensive Care Medicine, 2003, 29, 1489-1497.	3.9	192
188	Work hours reform: perceptions and desires of contemporary surgical residents. Journal of the American College of Surgeons, 2003, 197, 624-630.	0.2	96
189	Understanding Biased Selection in Medicare HMOs. Health Services Research, 2003, 38, 961-992.	1.0	79
190	Medical Monitoring for Pharmaceutical Injuries. JAMA - Journal of the American Medical Association, 2003, 289, 889.	3.8	5
191	The McLawsuit: The Fast-Food Industry And Legal Accountability For Obesity. Health Affairs, 2003, 22, 207-216.	2.5	55
192	The Leapfrog Standards: Ready To Jump From Marketplace To Courtroom?. Health Affairs, 2003, 22, 46-59.	2.5	18
193	Hospitals' Behavior In A Tort Crisis: Observations From Pennsylvania. Health Affairs, 2003, 22, 225-233.	2.5	17
194	Direct-to-Consumer Advertising and Shared Liability for Pharmaceutical Manufacturers. JAMA - Journal of the American Medical Association, 2003, 289, 477.	3.8	19
195	The New Medical Malpractice Crisis. New England Journal of Medicine, 2003, 348, 2281-2284.	13.9	211
196	Due Process in Investigations of Research Misconduct. New England Journal of Medicine, 2003, 349, 1280-1286.	13.9	23
197	Reduced Medicolegal Risk by Compliance With Obstetric Clinical Pathways. Obstetrics and Gynecology, 2003, 101, 751-755.	1.2	21
198	Results of a clinical trial on care improvement for the critically ill. Critical Care Medicine, 2003, 31, 2107-2117.	0.4	101

#	Article	IF	CITATIONS
199	Implementing Resident Work Hour Limitations. Annals of Surgery, 2003, 237, 449-455.	2.1	109
200	Nature of Conflict in the Care of Pediatric Intensive Care Patients With Prolonged Stay. Pediatrics, 2003, 112, 553-558.	1.0	141
201	Patient Safety and Medical Malpractice: A Case Study. Annals of Internal Medicine, 2003, 139, 267.	2.0	29
202	The Rise of Litigation in Human Subjects Research. Annals of Internal Medicine, 2003, 139, 40.	2.0	67
203	Policing Medicaid and Medicare Managed Care: The Role of Courts and Administrative Agencies. Journal of Health Politics, Policy and Law, 2002, 27, 465-494.	0.9	6
204	Do Medicare HMOs still reduce health services use after controlling for selection bias?. Health Economics (United Kingdom), 2002, 11, 323-340.	0.8	83
205	Demystifying the Law/Science Disconnect. Journal of Health Politics, Policy and Law, 2001, 26, 429-438.	0.9	1